Needle vs. IV: new shot for tough myeloma shows promise
NCT ID NCT04045795
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 26 times
Summary
This study tested a cancer drug called isatuximab given either as a shot under the skin or through an IV, along with two other medicines (pomalidomide and dexamethasone), in 56 adults with multiple myeloma that had returned or stopped responding to prior treatments. The main goals were to check safety, how the body processes the drug, and whether the shot form works as well as the IV form. This is a disease-control study, meaning it aims to manage the cancer rather than cure it.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Site Number : 8400002
Duarte, California, 91010, United States
-
Gabrail Cancer Center Site Number : 8400001
Canton, Ohio, 44718, United States
-
Investigational Site Number : 0360001
Wollongong, New South Wales, 2500, Australia
-
Investigational Site Number : 0360002
Blacktown, New South Wales, 2148, Australia
-
Investigational Site Number : 0360003
Richmond, Victoria, 3121, Australia
-
Investigational Site Number : 0360004
Fitzroy, Victoria, 3065, Australia
-
Investigational Site Number : 0560001
Leuven, 3000, Belgium
-
Investigational Site Number : 2500001
Nantes, 44093, France
-
Investigational Site Number : 2500002
Toulouse, 31059, France
-
Investigational Site Number : 3920001
Shibuya-ku, Tokyo, 150-8935, Japan
-
Investigational Site Number : 3920002
Okayama, Okayama-ken, 701-1192, Japan
-
Investigational Site Number : 7240001
Badalona, Catalunya [Cataluña], 08916, Spain
-
Investigational Site Number : 7240002
Santander, Cantabria, 39008, Spain
-
~Banner MD Anderson Cancer Center Site Number : 8400005
Gilbert, Arizona, 85234, United States
Conditions
Explore the condition pages connected to this study.